Please assess the completion status of the following clinical trial:

Trial Title: Safety and Effectiveness of Transdermal Buprenorphine in Cancer Pain

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Cancer patients aged 20 years old and over~2. ECOG \<3~3. Moderate or severe pain intensity with stable titration from previous opioid analgesics, 7 days at least prior to enrolment and with the dose equivalent to oral morphine ranging from 60 to 120 mg/day in previous treatment~4. Cancer-related pain that requires treatment with continuous around-the-clock strong opioid analgesic~5. Patients who are going to start Transtec treatment per clinical judgment, according to the locally approved labeling, are eligible.~6. Patients who are able to communicate and fill out the questionnaire forms~7. Patient provided signed informed consent~Exclusion Criteria:~1. Patients diagnosed with non-cancer pain or unexplained pain~2. Patients who have constipation (CTCAE grade 3 and above)~3. Patients with uncontrolled or unstable cardiac disease~4. Abnormal lab results, with obvious clinical significance, such as ALT or AST\>= 3 fold of upper limit of normal value or liver function of Child C grade prior to study~5. ALT or AST \>= 5 fold of upper limit of normal value for patients with liver metastasis or primary liver cancer~6. Pregnant or nursing (lactating) women~7. Patients who are drug or alcohol abuse~8. Patients who have hypersensitivity to buprenorphine~9. Patients who are clinically unstable or have a life expectancy of less than 8 weeks making completion of the trial unlikely~10. With any contraindications or using prohibited medication per locally approved

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).